Why 'digital twins' could speed up drug discovery

Published On Dec 12, 2024, 7:08 PM

Adsilico is leveraging artificial intelligence to create multiple digital twin models of the human heart, which can help in testing cardiovascular devices more effectively and inclusively. This innovation aims to enhance the safety of medical devices by enabling extensive virtual testing that encompasses a variety of patient anatomies and health conditions. Such technology could significantly reduce testing durations and costs for drug and device manufacturers, potentially leading to a higher success rate in clinical trials. Companies like Sanofi are also adopting digital twin technology to save time and money in their clinical testing processes, highlighting the economic benefits of this AI-driven approach.

Read full article

Stock Forecasts

ADSKView ADSK chart on TradingView

Positive

The success of digital twin technology in improving the accuracy and safety of medical device testing suggests a positive outlook for companies involved in AI healthcare solutions. Companies that develop or implement these technologies are likely to see increased demand, especially from the pharmaceutical sector looking to mitigate high clinical trial costs. As investment in AI healthcare solutions grows, their stock performance could improve significantly.

Related News